Which antifungal agent is commonly used as first-line therapy for aspergillosis in this scenario?

• A. Voriconazole
• B. Fluconazole
• C. Itraconazole
• D. Caspofungin

Answer: (A)

Treating invasive aspergillosis requires an antifungal with strong activity against Aspergillus and good penetration into infected tissues. Voriconazole fits this role best because it reliably targets Aspergillus species and reaches the lungs and other sites effectively. Clinical trials showed that voriconazole improves survival compared with amphotericin B deoxycholate, establishing it as the preferred first-line therapy. It also offers convenient oral and IV use with good bioavailability.

Other options have limitations in this scenario. Fluconazole doesn’t have activity against Aspergillus. Itraconazole can be active but has variable absorption and less consistent outcomes in invasive disease. Caspofungin is active against Aspergillus but is typically not first-line for primary invasive disease and is used more often as salvage therapy or in combination in specific cases. Amphotericin B formulations are effective but carry more toxicity and do not demonstrate the same survival advantage in initial therapy as voriconazole. So, voriconazole is the best initial treatment choice for aspergillosis.